Alterity Therapeutics Ltd logo

Alterity Therapeutics Ltd(ATHE)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$1.52
11/20/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ATHE

11/20/2026: ATHE (1-star) is currently NOT-A-BUY. Pass it for now.

Alterity Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing disease-modifying treatments for neurodegenerative disorders. The company's primary strength lies in its lead candidate, ATH434, which targets alpha-synuclein aggregation and iron accumulation for conditions like multiple system atrophy. Its core investment opportunity hinges on clinical success and potential commercialization in high-unmet-need rare neurological diseases. Key risks include the binary nature of clinical trials, lack of commercial revenue, and consistent reliance on equity financing. The stock suits risk-tolerant growth investors willing to monitor upcoming clinical readouts and regulatory developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers potential high-growth upside tied to clinical binary events, offset by heavy early-stage development risks.
Momentum investorWeak fitMomentum fit is conditional on a positive Upturn signal and clinical catalysts driving short-term price spikes.
Value investorWeak fitLacks traditional fundamental value metrics like earnings, positive cash flow, or commercial revenue.
Dividend investorWeak fitThe company pays no dividends and reinvests all capital into clinical research.
Low-risk investorWeak fitHigh clinical development risk, price volatility, and lack of commercial revenue make it unsuitable for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience dramatic price swings around trial readouts and capital raises.
Valuation riskHighValuation relies heavily on speculative future cash flows from unapproved drug candidates.
Competition risk (neurodegeneration drug development)HighLarger pharmaceutical competitors possess greater financial resources to develop competing treatments.
Business qualityMediumThe company has a specialized scientific focus but lacks a diversified commercial portfolio.
Dividend incomeLow / noneNo dividends are paid to shareholders.
Execution riskHighSuccessful clinical trial execution and regulatory clearance are critical for survival.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 31.60M USD
Price to earnings Ratio -
1Y Target Price 13.25
Price to earnings Ratio -
1Y Target Price 13.25
Volume (30-day avg) 168.0K shares
Beta -0.02
52 Weeks Range 1.52 - 5.89
Updated Date 11/20/2026
52 Weeks Range 1.52 - 5.89
Updated Date 11/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.9

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
61.0%
Active BUY / eligible
64 / 105
30-Day BUY Count Change
+16
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
44.7%
Active BUY / eligible
17 / 38
30-Day BUY Count Change
+9

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit -31.99%
Avg. Invested days 18
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/20/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ATHE receives a 2-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, soft company fundamentals, and weak price momentum.

Company Fundamentals

★★★★★
ATHE has soft overall fundamentals (2 stars), with moderate financial health, weak growth momentum, and soft ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-88.4%), soft cash generation (FCF margin 0.0%), negative revenue growth (-100.0%).

Financial Health Rating

★★★★★
ATHE's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
ATHE's growth profile is soft, with the least-weak measure being earnings growth at -88.4% FY2026 versus FY2025. By comparison, while revenue growth (-100.0%, negative) and free-cash-flow growth (-96.7%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 2.2% (soft) and 75.6% of outstanding shares are publicly tradable (solid). Insider ownership is only 0.00%, which materially reduces the ownership score.

Top 5 Institutional Investors

Twin Lakes Capital Management, LLC 0.73%
Morgan Stanley - Brokerage Accounts 0.33%
Greenleaf Trust 0.32%
HB Wealth Management, LLC 0.31%
Citadel Advisors Llc 0.20%

Unit Economics (Per $1K Revenue)

★★★★★
ATHE generates approximately $-0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Weak margins explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 13.00%

Quantitative Style Profile

★★★★★
ATHE has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic R&D / Commercialization (Future)Potential future product sales or licensing milestones from pipeline candidates like ATH434.The company currently makes no commercial money and relies on equity funding while developing drugs.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 8.18M
Price to Sales(TTM) 8.75
Enterprise Value 8.18M
Price to Sales(TTM) 8.75
Enterprise Value to Revenue 113.99
Enterprise Value to EBITDA 0.75
Shares Outstanding 19.09M
Shares Floating 14.43M
Shares Outstanding 19.09M
Shares Floating 14.43M
Percent Insiders -
Percent Institutions 2.23

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.